A phase II study of tasisulam sodium as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma Full Text
Investigational New Drugs, 05/04/2012
Ryan CW et al. – Tasisulam at a target Cmax of 420µg/mL on day 1 of 21–day cycles demonstrated modest activity as second–/third–line treatment in patients with soft tissue sarcoma (STS). Grade 4 hematologic toxicity posed some challenges in these heavily pre–treated patients. Tasisulam dosing continues to be refined.